(+Video) Phase 3 trial of bezlotoxumab to prevent recurrence of Clostridium ... - Nature World Report

Merck & Co Inc. shared the results of phase III trials of its antibody, bezlotoxumab, which may prevent the recurrence of Clostridium difficile. The company, Merck, announced this at the International Conference on Antimicrobials and Chemotherapy and the International Congress of Chemotherapy (ICAAC/ICC) 2015 annual meeting.

A C. difficile infection can also lead to life-threatening complications such as severe swelling of the bowel from a build-up of gas (toxic megacolon). Spores of the C. difficile bacteria can be passed out of the human body in faeces (stools) and can survive for many weeks, and sometimes months, on objects and surfaces.

Read Full Story